WHO-linked reports and clinicians highlight hepatitis B’s death toll, low diagnosis rates, and calls for earlier treatment
The facts
- Reports citing the World Health Organization say hepatitis caused about 1.3 million deaths globally in 2024.
- Sources citing WHO data say about 287 million people worldwide are living with chronic hepatitis B or C.
- Sources say hepatitis B is responsible for most hepatitis-related deaths, accounting for about 85% of the total.
- Several sources report that hepatitis B deaths were higher in 2024 than in 2015, with an increase of about 17%.
- Multiple sources say hepatitis B and C often progress without symptoms, which contributes to underdiagnosis and delayed care.
- Several sources say untreated chronic hepatitis can lead to serious complications including cirrhosis, liver cancer, and liver failure.
- In India, sources describe a large hepatitis B burden, with one source citing about 29.8 million people living with chronic hepatitis B and another estimating roughly 30-35 million people affected.
- Sources indicate that current diagnosis and treatment coverage for hepatitis B is far below the WHO’s 2030 elimination targets, leaving the timeline for meeting those goals unresolved.
Context
Why are doctors and health officials emphasizing hepatitis testing?
Several sources say hepatitis B and C can remain asymptomatic for long periods, so people may not know they are infected until advanced liver disease develops. That is why clinicians and public-health campaigns are stressing screening and early diagnosis India News, Breakin…,India News, Breakin…,Hindu,HABERTURK.COM.
What are the main health risks if hepatitis B is not treated?
Sources say chronic hepatitis can damage the liver over time and may lead to cirrhosis, liver cancer, or liver failure. These long-term complications are a major reason hepatitis remains a leading infectious-disease killer Haber7.com,Hindu,Hindu,HABERTURK.COM.
What is known about India’s response?
News18 reports that India’s National Viral Hepatitis Control Programme, launched in 2018, focuses on prevention, early diagnosis, and universal access to treatment. At the same time, the Hindustan Times opinion piece says diagnosis and treatment rates remain well below WHO targets, suggesting major gaps still need to be closed News18,Hindustan Times.
Common ground, and where they split
- Common ground
- Silent progression, underdiagnosis, and low treatment coverage are letting a known, deadly hepatitis B burden advance into preventable liver disease and death.
- Where Left and Right split
- Health systems failing people who cannot get timely care, or institutions failing to execute proven detection and treatment.
How left and right read it
1.3 million deaths in 2024 is not a niche health problem; it is a mass failure to reach people before preventable harm becomes irreversible. When hepatitis B drives most of those deaths, often after silent progression and delayed care, while diagnosis and treatment remain far below stated goals, the urgent question is why access is still allowed to lag so far behind need.
Hepatitis caused about 1.3 million deaths globally in 2024, and hepatitis B accounts for most of them even as deaths are higher than in 2015. Silent progression, underdiagnosis, and treatment coverage far below stated targets show a basic failure to identify and treat a known threat. The priority is competent follow-through on what already works.
The receipts — 100 sources
Other coverage (100)
A news briefing built to show both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.